EP3846754B1 - Vorrichtung zur behandlung von herpeserkrankungen - Google Patents

Vorrichtung zur behandlung von herpeserkrankungen Download PDF

Info

Publication number
EP3846754B1
EP3846754B1 EP19761894.5A EP19761894A EP3846754B1 EP 3846754 B1 EP3846754 B1 EP 3846754B1 EP 19761894 A EP19761894 A EP 19761894A EP 3846754 B1 EP3846754 B1 EP 3846754B1
Authority
EP
European Patent Office
Prior art keywords
temperature
contact
treatment
skin
treatment surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19761894.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3846754A1 (de
Inventor
Daniel BÜNGER VON WURMB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermapharm AG
Original Assignee
Dermapharm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18192698.1A external-priority patent/EP3620142A1/de
Priority claimed from EP18192693.2A external-priority patent/EP3620141A1/de
Application filed by Dermapharm AG filed Critical Dermapharm AG
Publication of EP3846754A1 publication Critical patent/EP3846754A1/de
Application granted granted Critical
Publication of EP3846754B1 publication Critical patent/EP3846754B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/007Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/02Compresses or poultices for effecting heating or cooling
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001Body part
    • A61F2007/0002Head or parts thereof
    • A61F2007/0003Face
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001Body part
    • A61F2007/0002Head or parts thereof
    • A61F2007/0015Cheeks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001Body part
    • A61F2007/0002Head or parts thereof
    • A61F2007/0017Mouth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001Body part
    • A61F2007/0052Body part for treatment of skin or hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/007Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
    • A61F2007/0071Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating using a resistor, e.g. near the spot to be heated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/007Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
    • A61F2007/0071Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating using a resistor, e.g. near the spot to be heated
    • A61F2007/0073Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating using a resistor, e.g. near the spot to be heated thermistor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/007Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
    • A61F2007/0077Details of power supply
    • A61F2007/0078Details of power supply with a battery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0086Heating or cooling appliances for medical or therapeutic treatment of the human body with a thermostat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0087Hand-held applicators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0093Heating or cooling appliances for medical or therapeutic treatment of the human body programmed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0095Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator
    • A61F2007/0096Heating or cooling appliances for medical or therapeutic treatment of the human body with a temperature indicator with a thermometer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/02Compresses or poultices for effecting heating or cooling
    • A61F2007/0282Compresses or poultices for effecting heating or cooling for particular medical treatments or effects
    • A61F2007/0284Treatment of stings or bites

Definitions

  • the invention relates to a device for the hyperthermic treatment of a herpes disease on a skin, preferably a lip, wherein a control device is configured to treat a treatment area on an outside facing the skin by heating at least one heating element in a heating phase to a contact temperature of 43 - 47 ° C, while of contact of the treatment area with the skin, preferably the lip, and to maintain it in a treatment phase for a period of between 1 to 10 seconds.
  • Herpes is commonly known as an acute, primary or secondary viral disease of the skin and mucous membranes caused by infection by the herpes virus. It usually occurs as locally grouped, standing blisters, especially on the face (herpes facialis ), on the cheeks (herpes buccalis ), the nose (herpes nasalis ) and on the genitals (herpes genitalis ).
  • the initial infection often occurs in early childhood and without being recognized, but leads to the formation of antibodies and often to masking of the virus and colonization in body tissues, which leads to relapses in the virus carriers when the immune system is weak.
  • Cold sore creams e.g. B. used with the active ingredient aciclovir. These creams should be used at the first sign of herpes disease (burning, itching, tightness and redness), as they inhibit the growth of certain viruses (antiviral, virus DNA polymerase inhibitor). The duration of treatment is generally 5 days.
  • a device for the treatment of herpes diseases comprises a heating plate with a preferred size of 20 mm 2 , which is heated to 49°C - 53°C for a treatment time of preferably 10 - 15 seconds.
  • EP 3 269 340 A1 and WO 2018/011263 A1 known a hyperthermic treatment of herpes diseases, wherein in the WO 2018/011263 A1 preferred ranges of 49-53°C. for a duration of 10-15 sec are suggested.
  • the heating plate contacts the affected skin area of the lips, for example the red area or the position where blisters have already formed.
  • the application of heat leads to a containment of the proliferation of the causative pathogens through a neutralizing effect on the herpes simplex viruses.
  • the short-term heat treatment causes the itching of the herpes disease to be superimposed by stimulating temperature-sensitive nerves.
  • the WO 2006/125092 A2 discloses a device for the local treatment of skin disorders by means of heat application, including herpes.
  • the focus of WO 2006/125092 A2 lies in the provision of a replaceable cap for the device. 48°-53°C, among others, are disclosed as preferred temperature ranges for the treatment of skin disorders, with the temperature preferably being maintained for at least 30 seconds.
  • the U.S. 6,245,093 B1 concerns a device for the treatment of itching by means of heat. Treatment temperatures are disclosed for pruritus in a wide window of 46°C and 62°C, with no optimized parameter or control of temperature parameters for herpes treatment.
  • the WO 2007/082648 A1 describes a device for treating insect stings or bites by the application of heat.
  • the device has a flat body as a contact surface, which can consist of ceramics or gold, among other things.
  • the temperature is controlled passively via a temperature-dependent resistor and a manual switch to start and end the treatment, preferably within a range of 50°C - 65°C
  • a hyperthermic treatment device for insect bites is known, treatment temperatures of 50-65° C. preferably being maintained for a treatment period of 2-12 seconds.
  • the object of the invention was to provide a device which eliminates the disadvantages of the prior art.
  • a device should be provided which is suitable for the treatment of herpes, preferably cold sores, and is characterized by increased effectiveness, ease of use and compliance associated therewith.
  • hypothermic treatment of a herpes treatment on the skin is understood in the context of the invention as a treatment of herpes diseases, preferably herpes labiales , which alleviates the symptoms of herpes by application of a defined amount of heat and treats the disease or inhibits its progression.
  • the treatment of herpes diseases thus relates in particular to the treatment of reddening, swelling, itching or other symptoms associated with herpes, in particular a cold sore on the lips.
  • the regulation device ensures that the treatment area is guided by heating at least one heating element to a contact temperature of 43-47° C. while the treatment area is in contact with the skin, preferably the lip.
  • the contact temperature for the purposes of the invention, refers to the temperature which the treatment surface has on an outside facing the skin, while this temperature is present when the skin area is in contact, preferably a lip area.
  • a contact temperature and a non-contact temperature of the treatment surface a distinction is made between a contact temperature and a non-contact temperature of the treatment surface.
  • the non-contact temperature means the temperature of the treatment surface when it does not contact the skin or lip, but merely contacts air without thermal load, for example.
  • the temperature of the treatment surface is usually regulated by a heating element based on a non-contact temperature. That is, the parameters of the regulation devices are carried out using standardized measurements of a temperature profile without thermal load. With such regulation, a distinction is also not necessarily made between regulation of the temperature of the treatment surface on the side that faces or faces away from the skin.
  • the device according to the invention is characterized in that the contact temperature is in a narrow therapeutically effective range for herpes of 43-47°C, preferably 44.5°C-46.5°C, particularly preferably 45°C-46 °C.
  • the outside of the treatment area is that side of the treatment area which is accessible from the outside of the device and thus corresponds to the side which faces the skin when the device is used.
  • an outer side of the treatment area facing the skin this is primarily of an illustrative nature.
  • the inner side preferably refers to the side facing away from the skin.
  • the treatment surface is integrated into the housing surface, with the inside, in contrast to the outside, not being accessible or visible from the outside.
  • the device can have temperature sensors which measure the temperature of the treatment surface during contact with the Measure the skin, preferably the lip, and adjust the heating elements accordingly.
  • the target temperature of the control device for the reading of the temperature sensor can be adjusted so that the contact temperature is kept precisely within the specified range. For example, a correspondingly higher target temperature can be set based on experimental tests or calculations of the heat flow. This ensures that the contact temperature is present when the treatment area comes into contact with the skin, preferably the lip.
  • tests were able to show that human skin, in particular lips across different test subjects, have similar thermal properties, so that the experimental or theoretical results can be reliably transferred. It has also been shown in particular that the thermal properties of different extremities of a subject often differ more than identical extremities of different subjects, so that the thermal properties can be used to determine the contact temperature.
  • the outside of the treatment area facing the skin is first brought to the contact temperature in a heating phase. It is preferred that the heating phase does not require a longer period of time.
  • the heating-up phase should preferably not be more than 10 s, particularly preferably not more than 3 s. Excellent results have been achieved with heating times of 1-3 seconds.
  • the contact temperature is kept in the range of 43-47° C., preferably 44.5° C.-46.5° C., particularly preferably 45° C.-46° C., for the duration of the treatment phase. It can be preferred that the contact temperature is constant during the treatment phase. However, it can also be preferred that the contact temperature varies within the specified limits during the treatment phase.
  • the treatment phase preferably means a continuous period of time during which the regulation device, the side of the treatment area facing the skin, has a contact temperature in the specified range of 43-47°C, preferably 44.5°C - 46.5°C, particularly preferably 45 °C - 46°C.
  • the contact temperature is below the values.
  • the at least one heating element is preferably no longer heated by the control device, so that the contact temperature falls below the range of 43-47°C, preferably 44.5°C - 46.5°C, particularly preferably 45°C - 46°C falls.
  • a defined amount of heat is applied to the skin area in a controlled manner.
  • the defined heat pulse leads to a surprisingly effective therapy for herpes diseases, especially cold sores, without unpleasant pain or even burns occurring.
  • thermolability of the DNA-binding protein ICP8 can be exploited to effectively prevent the replication of the herpesvirus DNA.
  • TRPV1 thermal and capsaicin receptor TRPV1 is activated locally in the affected skin areas.
  • TRPV1 is involved in acute heat-induced pain in healthy skin and regulates, for example, the perception of heat at temperatures around 45° to 50°C. Activation of TRPV 1 also suppresses feelings of tension and itching and thus the accompanying symptoms of the herpes disease.
  • the highest possible temperature should be selected for the introduction of heat against herpes, on the other hand, the associated pain can lead to the treatment being stopped prematurely and thus not being successful.
  • the contact temperature is between 44.5°C - 46.5°C, more preferably between 45°C - 46°C.
  • a symptomatic outbreak of herpes could be avoided in studies and / or in the advanced stage, a visible and/or tangible fading away of the cold sore and redness within 2 days, sometimes within one day. This suggests that the above ranges represent an optimal treatment regimen.
  • the high therapeutic success of the treatment regimen can only be partially explained by the above-described thermolability of the DNA-binding protein of the herpes virus.
  • the body's own immune system seems to be supported for the mentioned temperature ranges of 44.5 °C - 46.5 °C, especially from 45 °C - 46 °C, so that there is a synergistic effect in relation to the success of the treatment for the narrow temperature range is responsible, which includes an inhibition of the replication of the herpes virus with simultaneous activation or support of the body's immune system.
  • the treatment surface preferably designates a material surface of the device which is in direct thermal contact with the skin area during the treatment.
  • the treatment area can represent a continuous area. It can also be preferred that the treatment area consists of several non-contiguous partial areas.
  • the size of the treatment area preferably relates in each case to the entire contact area over which a part of the skin experiences a heat impulse. In the case of a treatment area that consists of several partial areas, the size of the treatment area preferably corresponds to the sum of the individual partial areas. Such a division into sub-areas can be advantageous in certain manifestations of herpes, as well as in the treatment of certain parts of the body.
  • the treatment area is preferably at most 60 mm 2 .
  • the size of the treatment area is particularly preferably between 20 mm 2 and 50 mm 2 . With the size of the treatment area selected in this way, a treatment that is optimally adapted to the cause can take place, which optimizes the therapeutic efficiency and thus contributes to a more sustainable treatment success. It is particularly preferred here to select circular treatment areas.
  • the treatment surface is brought to the desired contact temperature with the aid of at least one heating element.
  • the treatment area corresponds to the surface of a heating plate, which is heated with the aid of a heating element, in which case a semiconductor component can be used, for example.
  • the treatment surface can also refer to a homogeneous material surface, which is tempered by several heating elements. For example, it may be preferable to use two or four heating elements in order to bring the treatment surface to the contact temperature particularly homogeneously and quickly. It can also be preferred to coat a heating plate comprising a heating element.
  • the treatment surface is preferably understood to mean the coating of the heating plate, so that the contact temperature preferably always indicates the temperature that is present on the side of the treatment surface facing the skin during contact of the treatment surface with the skin.
  • control device is preferably a processor, a processor chip, a microprocessor or a microcontroller, which is configured to regulate the temperature of the treatment surface using the at least one heating element according to the predetermined values for the contact temperature.
  • the component that can be heated by the control device, among other things by applying an electric current is preferably referred to as the heating element.
  • the at least one heating element is a component for which various embodiments are sufficiently known from the prior art.
  • the heating element can thus comprise a power resistor, in which a well-defined temperature is generated as a function of the current flow.
  • a field effect transistor (FET) can preferably be used to quantitatively control the current flow through the heating element.
  • FET field effect transistor
  • energy dissipation in the transistor itself is used to generate heat and bring the treatment area to the contact temperature.
  • FETs are particularly preferred as heating elements since they allow small dimensions due to their small size.
  • FETs are particularly reactive and ensure a particularly fast response behavior of the heating elements thanks to very dynamic heat generation and heat dissipation.
  • the control device can preferably control the contact temperature by specifying the power supply to the heating element.
  • the correlation between current flow and/or voltage at the heating element with the contact temperature during contact of the treatment area with the skin can be determined with the aid of a calibration, so that a desired contact temperature is always based on the calibration between 43°C and 47°C, preferably between 44.5°C - 46.5°C, particularly preferably between 45°C - 46°C.
  • control device may also be preferable for the control device to regulate the contact temperature with the aid of a feedback loop. It can thus be preferable to use a temperature sensor which measures a temperature at a position on the treatment area, with the control device regulating the power supply to the heating element on the basis of the temperature data.
  • the control device can include a microprocessor, for example.
  • a microprocessor is preferably a data processing device, i.e. a processor, which is characterized by small dimensions in the range of a few mm and in which all the components of the processor are preferably on a microchip or also an integrated circuit ( IC ).
  • the microprocessor can preferably also be a microcontroller which, in addition to the processor, integrates further peripheral elements on the microchip and, for example, also has a data memory.
  • the microprocessor is installed on a printed circuit board (PCB).
  • PCB printed circuit board
  • the heating elements and the temperature sensors are also preferably installed on the PCB. This preferred embodiment allows an extremely compact and equally robust construction of the device and a particularly intelligent temperature regulation with the aid of the microprocessor.
  • the microprocessor is not only able to evaluate the measured temperature data and translate it into a controller for the heating elements, but can also quickly and reliably take into account other parameters such as error messages and user input.
  • the device is characterized in that the microprocessor and the heating element and optionally a temperature sensor are installed on a printed circuit board (PCB), at least the heating element and the temperature sensor being coated with a protective lacquer.
  • the protective lacquer is preferably understood to mean a lacquer or paint which is intended to protect components of the PCB from environmental influences.
  • the protective lacquer preferably has an electrically insulating effect and is water-resistant.
  • the property of electrical insulation can preferably be based on the surface resistance or Engl. surface insulation resistance (SIR) can be quantified.
  • SIR surface insulation resistance
  • the SIR can preferably be measured, for example, by leakage currents between the components of the printed circuit board. A high resistance corresponds to a good electrical Isolation.
  • Water-resistant preferably means that the coated electronic components remain intact and no short circuits occur, even in the event of high humidity or the ingress of water. For example, water resistance can also be tested by measuring SIR under high humidity conditions.
  • a large number of protective lacquers are known in the prior art, which can preferably be used. Examples include protective coatings based on acrylic, silicone or polyurethane. By applying the protective coating in the area of the heating elements and temperature sensors, these are effectively protected against deposits, so that incorrect measurements by the temperature sensors can be avoided. On the one hand, this increases the accuracy with which the contact temperature can be set and, on the other hand, prevents the treatment surface from overheating due to an incorrect temperature measurement.
  • the heating phase is 1 second to 5 seconds, preferably less than 3 seconds and in particular 1 to 2 seconds.
  • a quick heating-up phase means that the desired temperature can be reached particularly quickly.
  • preferential healing effects can be achieved without unnecessarily supplying a user with heat and/or increasing the time effectively required for a treatment.
  • the amount of heat given off during the treatment can be determined with particular precision.
  • the lips of the subjects are unnecessarily irritated during a therapeutically ineffective heating phase.
  • the contact temperature of 43° C.-47° C., preferably 44.5° C.-46.5° C., particularly preferably 45° C.-46° C., which is therapeutically effective for a herpes treatment, is reached quickly and reliably.
  • the heating-up phase preferably characterizes the duration during which the outside of the treatment area is brought to a contact temperature of 43-47° C. by heating at least one heating element while in contact with the skin, preferably the lip. Due to the low thermal load of a treatment area, when the device is placed on the lip, an initial temperature of the treatment area that corresponds to the typical skin temperature of the lips (e.g. 32° C.) is set relatively quickly.
  • the heating-up phase therefore preferably characterizes the duration of the temperature rise from a natural endogenous one Skin temperature to the desired contact temperature during the treatment phase of 43°C - 47°C, preferably 44.5°C - 46.5°C, particularly preferably 45°C - 46°C.
  • the size of the treatment area is between 30 mm 2 and 50 mm 2
  • the contact temperature is between 44.5° C. and 46.5° C., preferably between 45° C. and 46° C contact temperature for a period between 2 to 5 seconds.
  • the size of the treatment area is between 30 mm 2 and 50 mm 2 , with the control device protecting the outside of the treatment area by heating at least one heating element during a heating phase of 1 second to 5 seconds, preferably less than 3 seconds and in particular 1 to 2 seconds to a contact temperature of between 44.5°C - 46.5°C, preferably between 45°C - 46°C, the control device being configured to maintain the contact temperature for a period of between 2 to 5 seconds .
  • the preferred maximum size of the treatment area of 60 mm 2 is ideal to cover all possible affected areas.
  • a treatment area between 20 and 50 mm 2 is suitable for covering all typically affected skin areas with only one application of the device.
  • a herpes treatment facility that has such a treatment area can be kept particularly compact. Device sizes corresponding to that of a lipstick can thus be achieved.
  • Such a compact device is readily worn permanently on the body or in a pocket, so that treatment can be carried out at any time. This significantly increases the success of the treatment.
  • the treatment area is preferably round, which is particularly suitable for the treatment of herpes, the affected skin areas of which are often approximately round in shape.
  • any three-dimensional shapes, in particular convex shapes, which are particularly suitable for the treatment of herpes, can also be used.
  • the shape of a lipstick can be used, with the user being encouraged to gently press the device during treatment. This can trigger a psychological effect that increases well-being during the treatment. Also, the amount of heat transferred can be improved.
  • An organic form can be used, which is particularly suitable for treating the lips in particular.
  • a combination of the size of the treatment area together with the preferably mentioned contact temperatures and treatment phase is particularly effective for treating herpes, especially on the lip areas.
  • the treatment area is large enough to also effectively cover adjacent areas and thus also effectively treat the border area of infected skin areas.
  • the maximum size of the treatment area is perceived as particularly pleasant without any painful sensations. This is particularly important in the sensitive area around the mouth, especially the lips. The best compliance values, ie the greatest willingness of the patients to actively participate and use the device, as well as the best therapeutic successes are recorded for subjects with the aforementioned parameters.
  • the device comprises at least one temperature sensor for measuring the temperature of the treatment area, with the control device regulating the at least one heating element based on the measurement data of the temperature sensor.
  • a temperature sensor is preferably an electrical or electronic component which generates an electrical signal as a function of the temperature at the sensor.
  • a large number of temperature sensors are known in the prior art, such as, for example, semiconductor temperature sensors, resistance temperature sensors, pyroelectric materials, thermocouples or oscillating crystals.
  • the control device is also preferably configured in such a way that it can record and evaluate the measured values of the temperature sensors in order to regulate the heating element or elements.
  • the heating elements can preferably be regulated by applying an electric current or a voltage. It is particularly preferred that the temperature sensor directly measures the temperature of the treatment surface, ie the temperature sensor is in contact with the treatment area, whereby the temperature sensor can be located both on the inside of the treatment area and on the outside of the treatment area, or it can be implemented in the treatment area.
  • the control device is configured to reliably adjust the contact temperature based on the measured temperature of the temperature sensor. For example, if the temperature sensor is placed on the inside of the treatment area, the control device will be configured to set the target temperature on the inside of the treatment area to a higher temperature than is desired on the relevant outside of the treatment area during contact. The difference between such a target temperature and the contact temperature to be achieved can be made available to the control device as reference data based on theoretical predictions about the heat flow within the treatment area when applied to a skin or based on calibration measurements.
  • the temperature sensor does not contact and monitor the treatment area directly, but rather the heating elements or a material point between the heating elements and the treatment area. In the case of several heating elements that heat the treatment area, it can also be preferred, for example, to place the temperature sensor between the heating elements.
  • the temperature of the treatment area can also be inferred from the measurement data for the temperature via the heating elements or a measurement point at a specific distance from the treatment area.
  • the contact temperature preferably means the average temperature of the outside of the treatment area while in contact with a skin during use of the device.
  • An evaluation of the temperature of the treatment area allows a particularly precise regulation of the at least one heating element in order to ensure an optimal temperature distribution on the outside of the treatment area and thus heat transfer to the skin areas to be treated.
  • the embodiment is characterized by a more targeted and controlled regulation.
  • the device is characterized in that the treatment surface and consists of a material which has a thermal conductivity at 45° C. between 20 W/mK and 400 W/mK, preferably between 100 and 350 W/mK.
  • the thermal conductivity also known as the thermal conductivity number
  • the thermal conductivity indicates the amount of heat that is conducted through the treatment surface when a temperature gradient is applied to it.
  • thermal conductivity In addition to thermal conductivity, heat transport depends on the thickness of the treatment area, the size of the treatment area and the temperature difference between the inside of the treatment area (contact with the heating elements) and the outside of the treatment area (contact with the skin).
  • the thermal conductivity is preferably specified as the ratio of the transported heat output in watts (W) per temperature difference in Kelvin (K) and per meter (m). Since the thermal conductivity can also change slightly depending on the temperature, the reference temperature given here is 45 °C.
  • the thickness of the treatment area also preferably refers to the extension of the treatment area between the outermost surface which contacts the skin and the innermost surface against which the heating elements bear.
  • the thickness of the treatment area can be between 0.2 mm and 5 mm, preferably between 0.5 mm and 2 mm.
  • the treatment surface comprises ceramic or gold. It is particularly preferred that the treatment surface is made of gold or ceramics. On the one hand, the materials ceramic and gold fall within experimentally determined, preferred ranges of thermal conductivity.
  • both ceramic and gold excel in treating herpes in surprising ways.
  • the materials develop an increased perceived pain overlay in the patient. This is surprising insofar as the effect can go beyond the pure temperature effect caused by thermally comparable materials.
  • gold and in particular ceramics are distinguished by a surprisingly high level of biological compatibility, which, coupled with a particularly low level of allergies to these materials, particularly distinguishes the use in a device for the treatment of primarily dermatological diseases.
  • a particularly preferred ceramic is aluminum nitride. This is characterized to a particularly high degree by exceptional biological compatibility and excellent thermal properties.
  • a treatment surface made of aluminum nitride is particularly electrically insulating, resulting in increased safety in use can be guaranteed. This is particularly advantageous, particularly in connection with the use of a protective lacquer, and leads to a synergistic increase in safety.
  • the advantage of using ceramics and in particular aluminum nitride is noticeable in that the treatment surface can be disinfected with a disinfectant without any problems and without deterioration of the surface, as a result of which an antimicrobial effect with the advantages mentioned above is achieved. Due to the increased safety when using protective lacquer in connection with a treatment surface made of ceramics and in particular aluminum nitrite, liquid disinfectants can be used safely and without any problems.
  • disinfectants can also be used on a gold surface.
  • the device is characterized in that the temperature sensor is on the inside of the treatment surface and the treatment surface is covered by a ceramic layer with a layer thickness between 50 ⁇ m and 2000 ⁇ m, preferably between 50 ⁇ m and 1500 ⁇ m and particularly preferably 50 ⁇ m and 1000 ⁇ m or also 50 ⁇ m and 500 ⁇ m.
  • the device is characterized in that the temperature sensor is on the inside or surface of the treatment area and the treatment area is covered by a gold layer with a layer thickness between 5 ⁇ m and 2000 ⁇ m, preferably between 50 ⁇ m and 1500 ⁇ m and in particular between 50 ⁇ m and 1000 ⁇ m or between 50 ⁇ m and 500 ⁇ m.
  • the aforementioned preferred layer thicknesses make it possible to set the contact temperature particularly precisely during use of the device and to keep it within a narrow temperature range. In the case of thicker treatment areas, it is possible to draw conclusions about the contact temperature on the basis of calibration curves or theoretical calculations, starting from a temperature measurement on the inside of the treatment area.
  • the temperature sensors By implementing the temperature sensors on the inside a maximum of 1000 ⁇ m, preferably a maximum of 500 ⁇ m, 200 ⁇ m or less below the outside of the treatment area, a clearly reliable measurement statement about the contact temperature can be made. As part of a feedback regulation, the target temperature for the temperature sensor on the inside will only deviate slightly from the targeted contact temperature, which means that disruptive factors can be largely eliminated.
  • the aforementioned thin treatment layers thus allow a particularly precise regulation of the contact temperature to particularly preferred values of 44.5 to 46.5°C, preferably 45°C to 46°C. Particularly small tolerances of less than 1° C., preferably less than 0.5° C., 0.4° C., 0.3° C., 0.2° C. or 0.1° can also be achieved here.
  • the heating-up phase can advantageously be kept particularly reliably within short, preferred ranges of 1 second to 5 seconds, less than 3 seconds or 1 to 2 seconds by means of such thin layers of the treatment surface.
  • the device is characterized in that the treatment surface is formed by a ceramic and the temperature sensor is integrated into the treatment surface.
  • the temperature sensor can advantageously be brought extremely close to the outside facing the skin, independently of the thickness of the layer of the treatment area.
  • the embodiment is characterized by an additional degree of design freedom with regard to the layer thickness with equally precise regulation of the contact temperature.
  • a treatment area made of ceramic with a layer thickness of 0.5 to 2 mm, with the temperature sensor being integrated as a thin-layer sensor within the treatment area.
  • a particularly precise image of the heat flow can be obtained during the treatment.
  • the device comprises at least one contact sensor.
  • the contact sensor designates a unit which, on the basis of measurement data and their analysis, can make a statement as to whether the treatment area is in contact with skin, preferably a lip, or not.
  • the contact sensor preferably comprises a sensor or a measuring unit which is connected to the control device, with the control device being able to carry out the evaluation of the measurement data.
  • the contact sensor can include an optical sensor, which transmits the measurement data about the light conditions to the control unit. If the optical sensor is installed near or in the treatment area, a drop in brightness indicates that the treatment area is contacting a skin.
  • a contact sensor it can also be preferable for a contact sensor to refer to a unit consisting of a temperature sensor and the control device for regulating the heating elements, with the contact sensor being able to draw conclusions about the presence of skin contact based on the correlation between current flow and actual temperature.
  • contact sensors within the meaning of the invention can only make probable statements about contacting a skin based on measurable parameters, which characterize a skin in particular in contrast to air.
  • This can be, for example, the thermal property of the skin as a thermal load, electrical properties of the skin such as e.g. B. their conductivity and/or optical properties, such as their opacity, regarding.
  • determining skin contact is preferably to be understood as a measure of likely skin contact, as opposed to a condition where the treatment area is exposed to air.
  • a particularly precise regulation of the heat flow for the treatment of herpes can be achieved by means of the contact sensor and the information about the point in time at which the treatment area contacts the skin. For example, the start of the heating phase can be made dependent on whether there is contact with the skin. The duration of the treatment phase can also be reliably recorded in order to monitor treatments that have been carried out and, if necessary, to adapt further applications accordingly.
  • the contact sensor also allows improved control with regard to safety aspects.
  • a contact sensor can be used to prevent the treatment surface from heating up without the user knowing or wanting it.
  • a contact sensor for example, accidental triggering of a heating process when the device is carried in a trouser pocket can be reliably avoided.
  • the use of a contact sensor is particularly advantageous with regard to the flexible carrying of mobile devices for the treatment of itching or herpes.
  • the use of a contact sensor thus enables, on the one hand, particularly energy-efficient operation, in which heating is only triggered if the contact sensor is actually in contact with a skin.
  • unwanted and dangerous heating up for example in a trouser pocket or next to sensitive devices, e.g. smartphones with plastic content, etc., is avoided.
  • a therapeutically effective temperature profile of the contact temperature can be achieved particularly precisely by means of a contact sensor. Based on the information from a contact sensor, a contact temperature of 43-47°C, preferably 44.5°C to 45 5°C, particularly preferably 45°C to 46°C.
  • the information as to whether there is contact with the skin or not can be used efficiently to prevent the temperature of the treatment area from exceeding the specified range. Instead, a targeted hyperthermic treatment only takes place after actual contact with the skin and only during this. Temperature peaks, which occur when the device is removed from the skin for a short time due to the thermal load that is no longer present, can be counteracted effectively. For example, it can be observed in known devices from the prior art without corresponding contact sensors that some subjects trigger heating at the same time as they hang up or even a little prematurely. Since there is no thermal load on the treatment surface in this phase, the temperature can quickly exceed the specified value. The result is a painful sensation as soon as the treatment starts. Similar undesired effects can occur if the devices are only briefly removed from the skin or lip and then placed back on during treatment.
  • a heating-up phase can be particularly preferably suppressed as long as the contact sensor does not confirm any skin contact. If the treatment is already in progress, based on the information from the contact sensor, an immediate correction can be made in the event of a brief loss of contact.
  • the control device can be configured, for example, in such a way that if contact (and therefore a thermal load) is confirmed, a higher heat output is provided than in the case of no contact and therefore a low thermal load.
  • the use of a contact sensor opens up a wide range of possibilities for ensuring a particularly targeted and precise control of the contact temperature or of the entire temperature profile of the treatment device.
  • a contact sensor is therefore of particular advantage for the treatment of herpes diseases, in which a particularly precise control of the temperature curve is necessary for a successful therapy.
  • a contact temperature that is as high as possible is necessary, particularly for the treatment of cold sores, in order to reduce the replication of the herpes viruses.
  • the skin area is particularly sensitive, so that subjects stop the treatment even if the defined treatment area is exceeded just a little.
  • control device is configured in such a way that the period of time of the treatment phase is determined depending on when contact of the treatment area with the skin is detected.
  • the duration of the treatment phase is determined depending on when contact of the treatment area with the skin is detected.
  • the device is characterized in that the control device is configured such that heating of the heating element is only initiated if contact of the treatment surface with the skin is detected or heating of the heating element is stopped as soon as it is detected that there is no contact between the treatment area and the skin.
  • heating up can be prevented, for example by accidentally actuating a switch when transporting the device. Unnecessary reheating, even though the user has already knowingly or unknowingly broken off the treatment, is avoided. This saves energy and protects against improper use.
  • the device is characterized in that the contact sensor is or comprises an optical detector.
  • an optical detector preferably refers to a sensor for electromagnetic radiation, preferably in the visible range, i.e. in a wavelength range of 400-700 nm.
  • An optical detector for the visible range is preferably also referred to as a light sensor.
  • the optical detector detects electromagnetic radiation in the infrared or ultraviolet range.
  • Various optical detectors are suitable for the purposes of the device, such as photocells, photomultipliers, CMOS sensors, CCD sensors, photodiodes, phototransistors or photoresistors.
  • the optical detector will be installed within the treatment area or in close proximity to the treatment area.
  • the control device can determine the presence of contact with the skin on the basis of the measured data on the change in the light intensity.
  • the control device can also include reference data, for example about average light intensities in ambient light or about threshold values below which the optical detector is at least partially or completely covered.
  • the embodiment is distinguished by a simple yet reliable implementation of a contact sensor, which is also associated with only low additional costs.
  • the device is characterized in that the contact sensor is a capacitive sensor or includes one.
  • a capacitive sensor preferably designates a sensor which detects the change in the electrical capacitance of one or more capacitors.
  • the capacitive sensor is preferably installed within the treatment area. As soon as this touches a part of human skin or a lip, the measured capacitance changes due to the coupling of the external capacitance. A capacitive sensor can thus reliably indicate contact with a skin area.
  • the device is characterized in that the contact sensor is a tactile sensor or includes one.
  • a tactile sensor is preferably understood to mean a sensor which can detect contact with the treatment area on a mechanical basis. The measurement principle is therefore preferably based on the fact that when the treatment area is placed on the skin, a pressure is applied which can be detected mechanically by means of the tactile sensor.
  • Various suitable tactile sensors are known to the person skilled in the art, for example these can comprise measuring springs or piezoelectric elements which detect an indentation or displacement of the entire treatment surface.
  • the device is characterized in that the contact sensor is or comprises a pyrometer.
  • a pyrometer designates a sensor for non-contact temperature measurement.
  • the non-contact temperature measurement is preferably based on the measurement of the thermal radiation which each body emits as a function of its temperature.
  • the pyrometer can therefore also be referred to as a radiation thermometer or infrared sensor. Determining the temperature of a body depends on its emissivity. Emissivity is the ratio of the radiated power of any body to the radiated power of a black body at the same temperature. The emissivity depends on the material. In addition, for certain materials it can change with wavelength, temperature or other physical quantities.
  • the pyrometer or the infrared radiator is offset in the treatment area, so that the temperature of objects that are in front of the treatment area or that are in contact with the treatment area can be measured.
  • a temperature which typically corresponds to the surface temperature on a skin, preferably a lip
  • contact with the skin can be determined on the basis of the data measured by the pyrometer. Approx. 28-34° C., preferably approx. 30-33° C., are particularly suitable as temperature ranges for this purpose.
  • Suitable wavelength ranges for measuring these temperature ranges are in the mid-infrared range, preferably between 3 and 20 ⁇ m.
  • the person skilled in the art knows various pyrometers which are suitable for the stated purposes.
  • the person skilled in the art can also use known technologies for non-contact temperature measurement, which are used in non-contact clinical thermometers.
  • the device is characterized in that the control device can determine whether the treatment surface is in contact with the skin on the basis of a correlation of the measurement data from the temperature sensor and data about the activation of the heating element.
  • the contact sensor is formed by a temperature sensor and a control device for controlling the heating elements. Contact measurement is based on the knowledge that the current flow required to reach or maintain a temperature depends on whether the treatment area is in contact with a thermal load (e.g. a skin). If the treatment area heats up when it comes into contact with the skin, heat is transferred, which must be compensated for by an increased supply of energy to the heating elements. By evaluating the course of current and temperature, reliable statements can be made as to whether the treatment area is in contact with skin. Reference data can preferably be provided to the control device for this purpose.
  • the embodiment is distinguished on the one hand by the fact that, for example, no separate optical or capacitive sensor is required to establish contact. Instead, means that the temperature monitoring device has can be specifically adapted to detect contact with the skin.
  • a particular advantage of this embodiment is that an actually desired contact with a skin can be differentiated very precisely from an accidental contact of the treatment area with other materials (for example the inner fabric of a trouser pocket).
  • the skin (like other materials) has a specific thermal fingerprint, which makes it possible to use the configuration of a contact sensor described above to determine the presence of contact with a skin in a particularly reliable manner.
  • the lip can convey a different thermal load than is the case for other parts of the skin.
  • optimization or adjustment of the contact temperature is therefore possible within slight limits.
  • the control device includes reference data relating to a correlation of the temperature of the treatment area with the activation of the at least one heating element if the treatment area is in contact with the skin or with air.
  • the reference data can include, for example, ratios between the measured temperature and the power supply required for this.
  • the reference data include such ratios for a temperature profile, so that it can be determined particularly precisely, based on the measurement of the current ratio of temperature and power supply, whether the treatment area is in contact with skin.
  • a regulation can be used to reliably distinguish not only contact with the skin compared to air, but also contact with the skin compared to materials with other thermal properties.
  • the reference data can comprise the average amount of heat given off at the skin or the air.
  • the reference data can contain correlations between contact temperature and heat given off.
  • reference data can also be recorded for different skin areas, for example the lips or the face, in order either to obtain a particularly meaningful average value or, as explained above, to optimize the course of treatment depending on the type of skin contact detected.
  • the device comprises a waterproof housing.
  • the housing preferably represents an outer casing of the device, so that it in particular encloses the control device and other electronic components. It is preferred that the housing has a housing head and a housing handle, with the treatment surface preferably being at a lower portion of the housing head. In order to control and regulate the temperature of the treatment surface, the housing preferably has an opening at the corresponding position.
  • the housing is designed in such a way that all openings, ie for example battery compartments that may also be present, are watertight. For example, sealing rings or suitable seals, for example made of elastomers, can be used for this purpose.
  • sealing rings or suitable seals for example made of elastomers, can be used for this purpose.
  • the person skilled in the art knows many other technical options for constructing a waterproof housing.
  • the watertight design of the housing represents an (additional) safety element, since this effectively prevents damage to the control device or other electronic components due to the ingress of liquids.
  • the waterproof housing also leads to the prevention of corrosion and thus to a longer service life Contraption.
  • Safety can be increased synergistically, particularly in connection with the use of protective lacquer. This plays a role in particular in the disinfection processes of the device and above all of the treatment area.
  • the device can thus be thoroughly disinfected in a very simple and error-free manner by preferably dipping or placing the entire device in a disinfecting liquid and leaving it there for a certain minimum period of time.
  • the device comprises further safety elements which control the temperature of the treatment area.
  • the device can preferably include a hardware-implemented temperature monitor, which limits the maximum temperature of the treatment area to a value between 54°C and 58°C, preferably approximately 56°C.
  • the hardware-implemented temperature monitor advantageously makes it possible to ensure that a maximum temperature does not exceed a value between 54° C. and 58° C., preferably approximately 56° C.
  • the "hardware-implemented temperature monitor” preferably refers to a temperature control system for the treatment surface, which hardware-based can switch off the power supply to the heating elements for the treatment surface.
  • the "hardware-implemented temperature monitor” preferably allows the power supply to the heating elements to be switched off when the maximum temperature is exceeded, independently of the regulation of the heating elements by the control device, e.g. the microprocessor. If, for example, firmware is installed on the control device to regulate the heating elements, it is preferable for the hardware-implemented temperature monitor to reliably limit the maximum temperature of the treatment area even if the firmware fails or is executed incorrectly.
  • the maximum temperature is selected from a range of 47°C and 58°C. Intermediate ranges from the aforementioned ranges can also be preferred, such as 47°C-48°C, 48°C-49°C, 49°C-50°C, 50°C-51°C, 51°C-52° C , 52 °C - 53 °C, 53 °C - 54 °C, 54 °C - 55 °C, 55 °C - 56 °C, 56 °C - 57 °C or also 57 °C - 58 °C .
  • a person skilled in the art recognizes that the aforementioned range limits can also be combined in order to obtain further preferred ranges for the maximum temperature, such as 47°C to 50°C, 50°C to 54°C or even 48°C to 52°C.
  • the hardware-based temperature monitor can advantageously ensure at all times that the treatment surface has a maximum temperature of between 47 °C and 58 °C, preferably 54 °C and 58 °C C preferably does not exceed about 56°C.
  • This additional technical element for monitoring the temperature makes it possible to maintain an excellent standard of safety without interfering with the functioning of the hyperthermic treatment device.
  • a contact sensor can effectively avoid thermal overshoot in a functional controller. Is it also possible to use maximum values for the hardware-implemented temperature monitor, which are particularly low or particularly close to the desired treatment range.
  • a contact sensor In the case of a desired contact temperature of 43°C to 47°C, for example, it may be preferable to set a maximum temperature between 48°C and 54°C, preferably 50°C to 54°C. Without a contact sensor, the temperature ranges can be reached for a short time in the event of a loss of contact or the associated absence of a thermal load. As described above, a contact sensor can be used to prevent such an overshoot. Conversely, this means that when using a contact sensor, exceeding the desired temperature range already indicates a faulty function of the firmware with a high degree of probability, which justifies an intervention by the temperature monitor.
  • the device can have a safety fuse, which interrupts the power supply to the device in the event of a short circuit in the device or unregulated heating of the device.
  • a safety fuse is preferably understood to mean an overcurrent protection device in which a circuit can be interrupted, for example by the melting of a fusible conductor, as soon as the current strength exceeds a limit value for a period of time to be determined. It is preferred that the safety fuse is present in the device between the feeding of the supply voltage into the device and the device itself. Should an incident occur, which is characterized in that an uncontrolled high current flows from the supply feed into the device, the safety fuse advantageously switches off the entire voltage supply of the device. A fuse provides sufficiently fast and extremely reliable protection.
  • the heating-through heating of the heating elements is preferably understood to mean that the temperature of the heating elements rises in an uncontrolled manner, i.e. not by temperature-based regulation using the control device. If the hardware-implemented temperature monitor fails in these incidents, the treatment area can rise uncontrollably to temperatures well above the desired contact temperature, for example to temperatures well above 65 °C.
  • the safety fuse is therefore suitable for being able to ensure that the heating of the treatment area is switched off even in the most improbable case of a fault.
  • the power supply of the device represents a central regulation interface that satisfies the highest security requirements.
  • the hardware-implemented temperature monitor is advantageously set in such a way that the power supply of the device does not have to be permanently switched off. Rather, the hardware-implemented temperature monitor is designed in such a way that if the temperature of the treatment surface exceeds a maximum temperature, the power supply to the heating elements is interrupted while the temperature is being exceeded. The power interruption by the hardware-implemented temperature monitor is thus advantageously reversible, i.e. as soon as the temperature of the treatment area falls below the maximum temperature again, the heating elements can heat up again.
  • the intended use of the device can be continued even after a single occurrence of a faulty control.
  • the user might not notice anything about the faulty control, since the selected maximum temperature, the effectiveness and the independence of the hardware-implemented temperature monitor do not result in temperatures that the user finds uncomfortable and the device could function properly again the next time it was used in the event of a single faulty control.
  • the hardware-implemented temperature monitor comprises at least a second temperature sensor for measuring the temperature of the treatment area and a comparator, the comparator comparing the temperature of the treatment area with the maximum temperature and, if the maximum temperature is exceeded, interrupting the power supply to the at least one heating element.
  • a comparator preferably designates an electronic circuit for comparing two voltages, with the output indicating in binary form which of the two voltages is higher.
  • comparators are known in the prior art which are suitable for outputting a binary output signal from two analog voltages, which states which of the input voltages is higher.
  • the Schmitt trigger is an example of a comparator circuit.
  • a reference value for a voltage is applied at an input of the comparator using a Voltage distributor.
  • This reference value preferably corresponds to the voltage value which the second temperature sensor would have if the temperature of the treatment area is equal to the maximum temperature.
  • the output voltage of the temperature sensor which depends on the temperature of the treatment surface, is preferably present at the second input of the comparator.
  • a particularly preferred temperature sensor comprises an NTC thermistor, ie a thermistor. This has a negative temperature coefficient, so that when the temperature increases, the resistance drops and a higher current flows.
  • PTC thermistors ie PTC thermistors, which have a positive temperature coefficient, so that when the temperature increases, the resistance increases and a lower current flows.
  • the voltage value at the comparator moves towards the reference value of the voltage, which corresponds to the maximum temperature.
  • the output signal at the comparator changes in binary.
  • the comparator is preferably integrated into the power supply for the heating elements. This means that before the temperature of the treatment area reaches the maximum temperature, the comparator preferably releases the supply voltage for the heating elements. However, as soon as the temperature is higher than the maximum temperature, the output of the comparator switches off and interrupts the supply voltage to the heating elements. If the temperature of the treatment area falls again, the supply voltage is advantageously released again by the comparator.
  • the heating elements can be switched on and off reversible only for the period of time during which the temperature of the treatment surface exceeds the maximum temperature.
  • the comparator is enabled by the control device when starting the device. If the device does not start properly, the comparator is configured by default in such a way that the voltage supply to the heating elements is interrupted.
  • the described preferred embodiment of the hardware-implemented temperature monitor has proven to be particularly robust and reliable in tests. Due to the reversibility of the safety shutdown and the simple construction, the preferred embodiment is further characterized by low manufacturing and maintenance costs.
  • the design which is independent of the control device and includes its own temperature sensor, can ensure reliable operation even if a component of the control device fails.
  • a hardware-implemented temperature monitor in the form described using a comparator is particularly fast, since comparators are widely used electronic components which, in addition to their reliability, are characterized by their fast switching capability. For example, there are comparators with switching times of ns and below.
  • the device is characterized in that the safety fuse has a threshold value for a maximum current, which corresponds to heating the treatment surface to a value between 65°C and 70°C, preferably 65°C for 1 second. Tests have shown that only a temperature increase of more than 65 °C for longer than 1 second is very critical for the perception of pain and can lead to damage to the skin.
  • the fuse is not triggered prematurely in the event of non-critical temperature increases in the treatment area. As a result, profitability can be increased without making any compromises in terms of safety.
  • the specialist Based on the electrical parameters of the heating elements, the specialist knows which safety fuse should be selected in order to guarantee the specified values.
  • the current supply can also be measured with a simultaneous measurement of the temperature of the treatment area.
  • a fast-acting fuse which reacts to an increase in current within preferably less than 20 ms. It was recognized that even a short-term increase in current of less than 20 ms can lead to a temperature increase of longer than 1 second due to the thermal inertia of the treatment area.
  • a current-dependent fuse has a number of advantages.
  • the melting does not occur when a current above a threshold value is applied, but only when an external temperature is applied which is greater than a defined maximum temperature.
  • current-dependent fuses can therefore already react before a certain undesirable temperature is even reached as a result of a longer-acting increased current.
  • non-resetting, purely temperature-dependent thermal fuses always require a certain response time when an external temperature is present that is greater than a defined maximum temperature. This can lead to dangerous further temperature increases.
  • current-dependent fuses react faster and with minimal system-related latency times.
  • the device is characterized in that the threshold value of the safety fuse is preferably between 1 A and 2.5 A, particularly preferably around 2 A. Tests have shown that in relation to the preferred heating elements, the threshold values mentioned are particularly reliable in ensuring that the temperature of the treatment surface does not exceed a temperature of 65°C to 70°C for longer than 1 second. By melting the safety fuse from current values of 1 A to 2.5 A, it can be ensured that the temperature of the treatment area does not reach a health-endangering range. In a regular treatment, a regular treatment current of less than 2.5 A, preferably 1 A, occurs. If an error occurs, e.g. in the event of overheating, an increased current will flow. In this case, the fuse intervenes and effectively prevents uncontrolled heating.
  • the device is characterized in that the device comprises a power supply unit and a voltage monitor which monitors the voltage of the power supply unit.
  • the power supply unit preferably provides the electrical energy for operating the device.
  • Preferred power supply units are batteries or rechargeable batteries. These usually provide the electrical energy by providing a DC voltage.
  • the voltage provided by the power supply unit is monitored using a voltage monitor.
  • a voltage monitor preferably designates an electrical circuit that can measure the voltage of the power supply unit and triggers an action if it falls below a predetermined limit value.
  • a large number of variants for voltage monitors are known in the prior art, with the person skilled in the art knowing which voltage monitor is suitable for which types of power supply units, ie in particular batteries or accumulators. It is preferred that if the voltage monitor detects a drop in the voltage of the power supply unit below a certain value, it sends an interrupt request (IRQ ) to the control device, which is preferably a microprocessor. If a treatment cycle, ie a heating up or a treatment phase, is being run through during this time, the interrupt request leads to the treatment cycle being aborted. This provides another security mechanism It was found that an undervoltage on the power supply unit can lead to a failure of the control device, eg the microprocessor.
  • IRQ interrupt request
  • the voltage monitor can thus also contribute to increasing the safety of the device and avoiding a health hazard in the event of a faulty battery, for example.
  • the device is characterized in that the device includes a data memory for storing the system data and/or error messages.
  • Preferred system data includes a treatment cycle counter, which preferably separately counts the use of different types of treatment cycles. If, for example, a short or a long treatment cycle can be selected, these are counted separately.
  • the system data preferably includes a boot counter, ie a counter for how often the device was started and an indication of the error messages with the current error status.
  • a "reset” indicates that the voltage monitor has triggered a reset.
  • a “watchdog” indicates that a watchdog reset has occurred in the firmware, i.e. a system restart due to a software error.
  • For the error message it can preferably be determined in which program mode the device was located when the error occurred.
  • a "Temperature too high” can indicate that the temperature measured by the temperature sensor is too high, or that the temperature sensor is defective.
  • a “temperature too low” can indicate that the temperature measured by the temperature sensor is too low, or that the temperature sensor is defective.
  • a “Contact temperature reached” can indicate whether the desired contact temperature has been reached or an error has occurred during the preheating phase.
  • the stored system data and error messages can advantageously be used for diagnosis and troubleshooting for the device.
  • this data can be read out when a customer sends in a defective device.
  • the data it is possible to correlate the error that has occurred, eg "temperature too high", with other system data on the number of treatment cycles or watchdog resets.
  • the security features of the device can be continuously optimized both during the development phase and afterwards.
  • the possibility that the device includes storage of system data and error messages thus allows continuous improvement of the hardware and Software components of the device based on meaningful data.
  • the device is characterized in that firmware is installed on the control device, which controls at least the temperature regulation of the treatment surface, the firmware comprising a watchdog counter (WDC) which monitors whether the firmware is running.
  • firmware is preferably software, i.e. the instructions for a computer-implemented method, which is preferably embedded in the microprocessor in the control device.
  • the firmware preferably includes the software that is functionally connected to the hardware of the device, i.e. in particular to the heating elements and temperature sensors.
  • the firmware is preferably executed when the device is started and takes over the monitoring and control function of these hardware components of the device.
  • the control device evaluates, preferably on the basis of the firmware, e.g.
  • hardware-implemented components preferably designate components whose function is ensured independently of correct execution of the firmware.
  • the temperature monitor is implemented in hardware so that its function, i.e. a limitation of the maximum temperature, can take place independently of a correct execution of the firmware on the control device. Even if the firmware system crashes, the hardware-implemented temperature monitor can quickly and correctly limit the maximum temperature of the treatment area.
  • the firmware of the control device is monitored using a hardware-implemented watchdog counter. It is particularly preferably a time-out watchdog.
  • the time-out watchdog is preferably activated by the firmware before the start of the treatment phase.
  • the firmware sends a signal to the time-out watchdog within a predetermined time interval in order to reset it. If the time-out watchdog is not reset, this preferably leads to a restart of the firmware.
  • the time interval is preferably based on the time provided for carrying out a temperature measurement and regulation of the heating elements by the firmware and can be between 2 ms and 10 ms, for example.
  • Such a time-out watchdog can advantageously ensure that the firmware is functioning correctly and the temperature of the treatment area is monitored at least during the treatment phase of the device.
  • a hardware-implemented watchdog for monitoring the firmware preferably with the help of a time-out watchdog, for example, it can thus be ensured that if the firmware does not function correctly and the specified time interval is not observed, the treatment phase will be aborted.
  • the device thus has another safety feature in addition to the ones mentioned above, which, in particular in conjunction with the hardware-implemented temperature monitor, ensures that the treatment surface cannot overheat even if the firmware is not working correctly.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19761894.5A 2018-09-05 2019-09-05 Vorrichtung zur behandlung von herpeserkrankungen Active EP3846754B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18192698.1A EP3620142A1 (de) 2018-09-05 2018-09-05 Vorrichtung zur behandlung von herpeserkrankungen
EP18192693.2A EP3620141A1 (de) 2018-09-05 2018-09-05 Vorrichtung zur behandlung von juckreiz und herpeserkrankungen mit einem kontaktsensor
PCT/EP2019/073632 WO2020049071A1 (de) 2018-09-05 2019-09-05 Vorrichtung zur behandlung von herpeserkrankungen

Publications (2)

Publication Number Publication Date
EP3846754A1 EP3846754A1 (de) 2021-07-14
EP3846754B1 true EP3846754B1 (de) 2023-04-19

Family

ID=67809513

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19761894.5A Active EP3846754B1 (de) 2018-09-05 2019-09-05 Vorrichtung zur behandlung von herpeserkrankungen
EP19761893.7A Active EP3846753B1 (de) 2018-09-05 2019-09-05 Vorrichtung zur behandlung von juckreiz und herpeserkrankungen mit einem kontaktsensor

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19761893.7A Active EP3846753B1 (de) 2018-09-05 2019-09-05 Vorrichtung zur behandlung von juckreiz und herpeserkrankungen mit einem kontaktsensor

Country Status (10)

Country Link
US (2) US12502307B2 (pl)
EP (2) EP3846754B1 (pl)
JP (2) JP2022500105A (pl)
KR (2) KR20210058863A (pl)
CN (2) CN112638336A (pl)
ES (2) ES2950010T3 (pl)
PL (1) PL3846754T3 (pl)
PT (1) PT3846754T (pl)
TW (1) TW202023486A (pl)
WO (2) WO2020049070A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017009805A2 (pt) 2014-11-14 2017-12-26 Cytrellis Biosystems Inc dispositivos e métodos para ablação da pele
CN217366261U (zh) * 2022-01-24 2022-09-06 中山市特莱斯电子有限公司 一种止痒器
DE102022116008A1 (de) * 2022-06-28 2023-12-28 Kamedi Gmbh Heizplättchen mit ausnehmung
DE202024104366U1 (de) 2024-07-25 2024-09-05 Horst Dittmann E.K. Kompakte, multifunktionale Vorrichtung zur Behandlung von Insektenstichen
EP4686459A3 (de) 2024-07-25 2026-03-04 Horst Dittmann e.K. Kompakte, multifunktionale vorrichtung zur behandlung von insektenstichen
CN119556753B (zh) * 2025-02-05 2025-07-18 深圳市奥极健康科技有限公司 用于皮肤热疗止痒设备的温度检测控制方法及介质

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537605B2 (en) * 1993-10-04 2009-05-26 Huan-Chen Li Medical device for treating skin itch and rash
US6635075B2 (en) * 1993-10-04 2003-10-21 Huan-Chen Li Method and apparatus for treatment of skin itch and disease
US6245093B1 (en) 1993-10-04 2001-06-12 Huan-Chen Li Method and apparatus for treatment of skin itch and disease
CN1103210C (zh) * 1993-11-24 2003-03-19 李欢成 用热止痒及治皮疹粉刺的仪器
DE19954424A1 (de) * 1999-11-11 2001-06-07 Hansgeorg Schuldzig Einrichtung zur lokalen thermischen Behandlung von Insektenstichen und -bissen
US7137979B2 (en) * 2003-05-31 2006-11-21 Tyrell, Inc. Methods and devices for the treatment of skin lesions
CN2748051Y (zh) * 2004-09-28 2005-12-28 贺加赞 快速止痒仪
JP4989486B2 (ja) * 2004-12-10 2012-08-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 皮膚状態の治療のための装置及び方法
US20110015549A1 (en) * 2005-01-13 2011-01-20 Shimon Eckhouse Method and apparatus for treating a diseased nail
DE102005002946A1 (de) 2005-01-18 2006-07-27 Bsm - Bionic Solution Management Gmbh Herpesbehandlungseinrichtung
RU2007146978A (ru) * 2005-05-18 2009-06-27 Тирелл, Инк. (Us) Лечебное устройство и способ лечения кожных заболеваний под воздействием тепла
EP1971301A1 (de) 2006-01-13 2008-09-24 E.I.S. GmbH Handgerät und verfahren zum thermischen behandeln der durch einen insektenstich oder -biss betroffenen stelle
CN200957128Y (zh) * 2006-10-23 2007-10-10 周雷 快速、安全、有效的电子止痒仪
US20090264971A1 (en) * 2008-04-16 2009-10-22 Essentials By Amy Llc Dermatological Device for Providing Therapeutic Heat Treatment
KR101159779B1 (ko) * 2009-08-17 2012-06-26 (주)메딕콘 광 및 열을 병용하는 휴대용 피부 질환 치료기
US20110172750A1 (en) * 2010-01-11 2011-07-14 David Ellsworth Cassidy Methods and apparatus for active patient warming
WO2013076714A1 (en) * 2011-11-24 2013-05-30 Synerom Medical Ltd A safe skin treatment apparatus for personal use and method for its use
US20140352325A1 (en) * 2013-06-03 2014-12-04 Wendell Brown Electronic coldpack and method of use
US20150173996A1 (en) * 2013-12-20 2015-06-25 L'oreal Method for treating the skin and device
JP2016101467A (ja) * 2014-11-28 2016-06-02 豊成 原田 皮膚電熱器
KR102448859B1 (ko) * 2016-06-03 2022-10-04 알2 테크놀로지스, 인크. 피부 처리를 위한 냉각 시스템 및 방법
FI3269340T3 (en) 2016-07-12 2024-09-13 Dermapharm Ag DEVICE FOR HYPERTHERMAL TREATMENT OF ITCH
TWI772314B (zh) 2016-07-12 2022-08-01 德商得瑪法公司 用於瘙癢症的高熱治療之裝置
US11464702B2 (en) * 2016-08-05 2022-10-11 Koninklijke Philips N.V. Thermal skin treatment device
HUE051218T2 (hu) * 2016-10-11 2021-03-01 Dermapharm Ag Készülék viszketés hipertermikus kezelésére
DE102017006994A1 (de) * 2017-07-24 2019-01-24 Stefan Hotz Koppelbare portable Vorrichtung zur thermisch - medizinischen Behandlung der Haut

Also Published As

Publication number Publication date
ES2950010T3 (es) 2023-10-04
ES2935492T3 (es) 2023-03-07
KR20210058863A (ko) 2021-05-24
CN112638336A (zh) 2021-04-09
TW202023486A (zh) 2020-07-01
US20210322205A1 (en) 2021-10-21
WO2020049071A1 (de) 2020-03-12
EP3846753B1 (de) 2022-10-19
WO2020049070A1 (de) 2020-03-12
PT3846754T (pt) 2023-07-19
PL3846754T3 (pl) 2023-08-21
EP3846754A1 (de) 2021-07-14
EP3846753A1 (de) 2021-07-14
JP2022500105A (ja) 2022-01-04
US20210322204A1 (en) 2021-10-21
JP2021534918A (ja) 2021-12-16
US12502307B2 (en) 2025-12-23
KR20210062024A (ko) 2021-05-28
CN112638335A (zh) 2021-04-09

Similar Documents

Publication Publication Date Title
EP3846753B1 (de) Vorrichtung zur behandlung von juckreiz und herpeserkrankungen mit einem kontaktsensor
EP3484423B1 (de) Vorrichtung zur hyperthermischen behandlung von juckreiz
EP3308752B1 (de) Vorrichtung zur hyperthermischen behandlung von juckreiz
EP3685810A1 (de) Mobile vorrichtung zur behandlung von juckreiz mit schnittstelle
DE202016008836U1 (de) Vorrichtung zur hyperthermischen Behandlung von Juckreiz
EP3620142A1 (de) Vorrichtung zur behandlung von herpeserkrankungen
EP3620141A1 (de) Vorrichtung zur behandlung von juckreiz und herpeserkrankungen mit einem kontaktsensor
DE202018105061U1 (de) Vorrichtung zur Herpesbehandlung durch Wärmeanwendung
HK40049694A (en) Device for treating pruritus and herpetic diseases with a contact sensor
HK40049695A (en) Device for treating herpetic diseases
HK1250906B (en) Device for hyperthermal treatment of itching
HK1250906A1 (zh) 用於高温处理瘙痒的装置

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20221110

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502019007506

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1560671

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230515

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230509

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3846754

Country of ref document: PT

Date of ref document: 20230719

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20230714

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2950010

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230819

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502019007506

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20240122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230905

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20190905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20190905

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251001

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20250827

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250826

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250821

Year of fee payment: 7

Ref country code: NL

Payment date: 20250922

Year of fee payment: 7

Ref country code: TR

Payment date: 20250902

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20250919

Year of fee payment: 7

Ref country code: GB

Payment date: 20250923

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250922

Year of fee payment: 7

Ref country code: AT

Payment date: 20250918

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250930

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251001

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251020

Year of fee payment: 7